Related Experiment Video
Updated: May 19, 2026
09:40
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
MicroRNA-based integrated diagnosis and therapy for GBM: current status and advances
Ye Chen1,2, Huiyi Liu1,2, Peipei Yuan1,2
1Guangxi University of Chinese Medicine, Nanning, China.
Frontiers in Immunology
|May 18, 2026
Summary
MicroRNAs (miRNAs) delivered via exosomes show dual potential for glioblastoma (GBM) treatment and diagnosis. This approach offers targeted therapy and precise biomarkers for improved patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Molecular Biology
Background:
- Glioblastoma (GBM) is an aggressive brain cancer with poor prognosis.
- Current treatments offer limited efficacy, necessitating novel therapeutic and diagnostic strategies.
Purpose of the Study:
- To explore the potential of microRNAs (miRNAs) delivered by exosomes as a dual therapeutic and diagnostic tool for glioblastoma (GBM).
- To review the efficacy of exosome-miRNA systems in inhibiting tumor progression and serving as biomarkers.
Main Methods:
- Review of studies on exosome-based delivery systems for microRNAs (miRNAs).
- Analysis of the role of miRNAs in glioblastoma (GBM) proliferation, invasion, metastasis, and chemoresistance.
- Evaluation of exosome-miRNA systems in vitro and in vivo models.
Main Results:
- Exosome-delivered miRNAs effectively inhibit tumor cell proliferation, promote apoptosis, and reverse chemoresistance.
- Engineered exosome-miRNA systems demonstrate efficacy in suppressing tumor growth and enhancing treatment sensitivity.
- Aberrant miRNA expression in GBM correlates with disease progression and therapeutic response, suggesting biomarker potential.
Conclusions:
- MicroRNA (miRNA) systems, particularly when delivered via exosomes, offer a promising dual approach for glioblastoma (GBM) therapy and diagnosis.
- Further research is needed to optimize delivery efficiency and targeting specificity for clinical translation.
